Chromomycin A₅ induces bonafide immunogenic cell death in metastatic melanoma

Katharine G. D. Florêncio¹, Evelline A. Edson¹, Francisco C. L. Pinto², Otília D. L. Pessoa²
João Agostinho Machado-Neto³ and Diego V. Wilke^{1,*}

¹Drug Research and Development Center, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Ceara, Brazil, ²Department of Organic and Inorganic Chemistry, Sciences Center, Federal University of Ceara, Ceara, Brazil, ³Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.

Abstract

Some first-line cytotoxic chemotherapies, *e.g.* doxorubicin, paclitaxel and oxaliplatin, induce activation of the immune system through immunogenic cell death (ICD). Tumor cells undergoing ICD function as a vaccine, releasing damage-associated molecular patterns (DAMPs), which act as adjuvants, and neoantigens of the tumor are recognized as antigens. ICD induction is rare, however it yields better and long-lasting antitumor responses to chemotherapy. Advanced metastatic melanoma (AMM) is incurable for more than half of patients. The discovery of ICD inducers against AMM is an interesting drug discovery strategy with high translational potential. Here we evaluated ICD induction of four highly cytotoxic chromomycins A (CA₅₋₈). B16-F10, a metastatic melanoma cell line, treated with CA₅₋₈ and doxorubicin exhibited ICD features such as autophagy and apoptosis, externalization of calreticulin, and releasing of HMGB1. However, CA₅-treated cells had the best profile, also inducing ATP release, ERp57 externalization, phosphorylation of eIF2 α and altering expression of transcription of genes related to autophagy, endoplasmic reticulum stress, and apoptosis. Bonafide ICD induction by CA₅ was confirmed by a C57BL/6 mice vaccination

26 assay with CA₅-treated cells. These findings support a high potential of CA₅ as an anticancer
27 candidate against AMM.

28

29 **Keywords:** chromomycin A5; immunogenic cell death; metastatic melanoma; autophagy;
30 anticancer.

31

32 **Abbreviations:** AMM, advanced metastatic melanoma; AO, acridine orange; APC, antigen
33 presenting cell; AVOs, acidic vesicular organelles, CRT, calreticulin; DAMPs, damage-
34 associated molecular patterns; eIF2 α , eukaryotic initiation factor 2 α ; ER, endoplasmic
35 reticulum; HMGB1, high mobility group box-1; ICD, immunogenic cell death; PD-1,
36 programmed death-1; PD-L1, programmed death-1 ligand.

37

38 ***Corresponding author:** Diego Veras Wilke, Drug Research and Development Center,
39 Federal University of Ceara, Fortaleza, Ceara, Brazil, 60.430-275. E-mail:

40 diegowilke@gmail.com

41

42

43

44

45

46

47

48

49

50

51 1. Introduction

52 Advanced metastatic melanoma (AMM) is the most aggressive skin cancer, and is a serious
53 concern due to increasing incidence in recent decades. Chemotherapy with dacarbazine and
54 temozolomide was the standard of care in metastatic melanoma until 2011, however with no
55 benefit for overall survival (QUEIROLO et al., 2019). Immunological therapy with IL-2 induces
56 long-lasting responses in a small subset of patients, albeit with a high rate of severe toxicities
57 (ATKINS et al., 2016; QUEIROLO et al., 2019). Advances in AMM treatment have yielded
58 better agents based on target therapies, such as BRAF and MEK inhibitors (KAKADIA et al.,
59 2018) and immunological checkpoint inhibitors, e.g. anti-PD-L1, anti-PD-1 and anti-CTLA-4
60 antibodies (LARKIN et al., 2015; QUEIROLO et al., 2019). Despite these advances, more
61 than half of patients still do not experience a satisfactory clinical response. Thus translational
62 research should pay particular attention to the non-responders subset of patients, aiming to
63 shift immune-cold tumors into immune-hot ones (QUEIROLO et al., 2019).

64 The immunogenic effect of first-line chemotherapy and some radiotherapy treatments have
65 been revealed as the hidden ally which improves responses of patients (KEPP et al., 2014;
66 KROEMER et al., 2013; VANMEERBEEK et al., 2020). Treatment with inducers of
67 immunogenic cell death (ICD) produces a specific antitumor immunity, which potentiates
68 therapeutic efficacy (GALLUZZI et al., 2017; GARG et al., 2014; KEPP et al., 2014). ICD is a
69 rare type of regulated cell death characterized by the activation of the adaptive immune
70 system in the presence of cell death antigens, especially from cancer cells. Only 5% of
71 chemotherapeutics the arsenal approved by the Food and Drug Administration of USA for
72 cancer treatment are validated ICD inducers. However, they are first-line agents in the clinic
73 and among the most used in the world including anthracyclines, taxanes and oxaliplatin
74 (KEPP; SENOVILLA; KROEMER, 2014). This cell demise occurs under strong cellular stress,
75 including autophagy and endoplasmic reticulum (ER) stress, and release of a constellation of

76 damage-associated molecular patterns (DAMPs), the signals required to recruit and activate
 77 immune cells, such as antigen-presenting cells (APCs) and lymphocytes. The most important
 78 DAMPs in ICD include ATP, high mobility box group-1 (HMBG1), a nuclear non-histone
 79 nuclear factor, chaperones, specially calreticulin, and heat-shock proteins 70 and 90, annexin
 80 A1, CXCL10 and type I interferon (KROEMER et al., 2013; RADOGNA; DICATO;
 81 DIEDERICH, 2019). In addition to *in vitro* evaluation of cell demise associated with cell stress
 82 and release of DAMPs, a vaccination assay is required to validate induction of ICD through
 83 an anti-tumor response *in vivo* (GALLUZZI et al., 2020; VANMEERBEEK et al., 2020). Clinical
 84 evidence also supports ICD as a sensitizer to PD-1/PD-L1 blockade (KEPP et al., 2019). Thus
 85 identification of ICD inducers against AMM is a promising strategy for early identification of
 86 anticancer candidates with high expectation of translational success.

87 Chromomycins and mithramycins are promising antitumor antibiotic aureolic acids
 88 (KORMANEC et al., 2020). In 1970, mithramycin was approved for use in testicular cancer
 89 (BROWN AND TORKELOSON, 1995), and chronic and acute myeloid leukemia (SNYDER et
 90 al., 1991; DUTCHER et al., 1997). Recent studies have shown mithramycin inhibition of drug-
 91 resistant cancer-initiating stem cells, important players in the disease relapse (KORMANEC
 92 et al., 2020). Mithramycins also have been reported as an inhibitor of P-glycoprotein, a
 93 transmembrane efflux pump related to resistance to multiple drugs in cancer cells
 94 (TAGASHIRA et al, 2000).

95 Chromomycin A₃ has antitumor activity, reversibly binding to minor DNA grooves by
 96 interacting with cytosine and guanine (CG)-rich DNA regions in the presence of Mg²⁺,
 97 preventing replication and transcription (SUKANYA CHAKRABARTI1; BHATTACHARYYA,
 98 2000; CHAKRABORTY et al., 2014). Guimarães et al., (2014) showed chromomycin A₂
 99 induces autophagy in metastatic melanoma cells, MALME-3M. The pre-apoptotic autophagy
 100 is related to the immunogenic outcome of cancer cell death (MARTINS et al., 2012). Recently

we obtained four cytotoxic dextrorotatory chromomycins A (CA₅, CA₆, CA₇, and CA₈) from the actinobacteria *Streptomyces* sp. BRA-384 which displayed IC₅₀ values against five tumor cells from the pM to nM range (PINTO et al., 2019). CA₅ binds to the transcription factor T-box 2 (TBX2), which also may be related to its antiproliferative effect and antimetastatic potential (SAHM et al., 2020). Because CA₅₋₈ are highly cytotoxic (PINTO et al., 2019) and likely to induce autophagy of melanoma cells (GUIMARÃES et al., 2014), we hypothesized these compounds were bonafide ICD inducers. Here we investigated the induction of ICD by CA₅₋₈ on an AMM model, which could mark the renaissance of chromomycins as promising anticancer agents.

110

111 **2. Materials & Methods**

112 **2.1 Reagents**

Chromomycins (CA₅, CA₆, CA₇, and CA₈) were obtained as previously described by Pinto et al. (2019). Doxorubicin and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (Missouri, USA). All cytotoxic compounds were diluted in DMSO.

116

117 **2.2 Cell culture**

The murine metastatic melanoma B16-F10 cell line was purchased from Banco de células do Rio de Janeiro (Rio de Janeiro, Brazil) and cultured following the manufacturer's instructions.

120

121 **2.3 Animals**

We used a total of 21 C57BL/6 mice (female, 18–20 g) 6-8 weeks-old, free of ecto and endoparasites, obtained from the animal house of the Federal University of Ceara, Brazil. Animals were housed in cages under a 12:12 h light-dark cycle (lights on at 6:00 a.m.) and food and water *ad libidum*. All animal handling procedures were performed following the

126 Brazilian legislation for the use and care of laboratory animals (No 11.724/20080) after
127 approval by the Animal Ethics Committee of the Federal University of Ceara (No
128 3000310818).

129

130 **2.4 Antiproliferative assay**

131 Sulforhodamine B (SRB) assay was performed as described by Skehan et al., 1990. CA₅₋₈
132 0.32 to 1000nM (CA5, CA6, CA7 and CA8 respectively), doxorubicin at 0.6μM (Dox) as
133 positive control and DMSO (0.05%) as negative control were added to cells during 4h, 8h,
134 12h, 24h, 48h and 72h and antiproliferative effect evaluated after 72h. When the exposure
135 time was < 72h, cells were washed and replaced by fresh media (see Fig. 1). Inhibition
136 concentration mean (IC₅₀), total growth inhibition (TGI), and lethal concentration mean (LC₅₀)
137 values were calculated from cell growth percentage normalized data through interpolation of
138 nonlinear regression using GraphPad Prism v6 (GraphPad Software, Inc., San Diego, CA,
139 USA).

140

141 **2.5 Clonogenic assay**

142 The colony-forming assay was performed according to Franken et al., 2006. Briefly, cells were
143 seeded in 6-well plates at a density of 500 cells/well and exposed to CA₅₋₈ (CA5, CA6, CA7,
144 and CA8), doxorubicin (Dox) or 0.05% DMSO (C-) for 24 hours. After this period, the medium
145 with cytotoxic agents or DMSO was replaced by a fresh medium, and plates were analyzed
146 daily until the DMSO control reached a high density of individualized colonies (approximately
147 7 days). Cells were then washed with PBS and stained with violet crystal dye (0.5% crystal
148 violet in methanol 50% and distilled water). Total individual colonies/well were counted under
149 a stereoscopic microscope.

150

151 **2.6 Cell treatment for immunogenic cell death investigation**

152 Usually, 2.5×10^4 cells/mL were seeded in 24-well plates for flow cytometry assays, 96-well
153 for ATP assay, or in Petri dish plates (90 x 15 mm) for western blot and qPCR assays, and
154 incubated for 24 h before the treatment. Then cells were exposed to CA₅ at 0.1 μM (CA5),
155 CA₆ at 0.25 μM (CA6), CA₇ at 0.25 μM (CA7) and CA₈ at 0.5 μM (CA8), doxorubicin at 0.6 μM
156 (Dox), as the ICD inducer positive control, and 0.05% DMSO (C-), as the negative control,
157 and incubated for 2 hours. After treatment, cells were collected and washed with PBS before
158 all protocols described below.

159

160 **2.7 Cell viability - flow cytometry**

161 All flow cytometry assays were set to acquire 10,000 events excluding debris and doublets
162 using a FACSVerse™ flow cytometer (BD Biosciences, San Diego, CA, USA) and FlowJo
163 v10.6 software (Ashland, OR: Becton, Dickinson and Company) for data analysis. Cell
164 suspensions were incubated with 2 μg/mL 4',6-diamidine-2'-phenylindole dihydrochloride
165 (DAPI, Sigma-Aldrich, Missouri, USA) for 10 minutes as the final step in all flow cytometry
166 assays to distinguish membrane integrity and disruption, except for the acridine orange stain.

167

168 **2.8 Acidic vesicular organelles (AVOs) staining with acridine orange (AO) – flow** 169 **cytometry**

170 Differential acridine orange (AO) staining is an assay that is strongly correlated with
171 autolysosomes formation in the late step of autophagy. The AO assay was performed as
172 described previously (THOMÉ et al., 2016). Briefly, cells were washed with PBS and stained
173 with 1 μg/mL AO (Sigma-Aldrich, Missouri, USA) for 30 min in the dark at room temperature.
174 Excitation of AO-stained cells with a 488 nm laser induces green fluorescence in whole cells
175 and red fluorescence is produced in acidic vesicular organelles (AVOs) due to AO

metachromasia. AVOs were gated in a region with an increased ratio of red fluorescence. The increase of cell granularity, although nonspecific, is a relevant cell stress alteration found in autophagy and ER stress. High cell granularity was gated in the high side scatter (SSC) region.

2.9 Calreticulin (CRT) externalization – flow cytometry

Cells were fixed with 0.25% paraformaldehyde in ice-cold PBS for 5 min and incubated with anti-CRT (Calreticulin (D3E6) XP Rabbit mAb, Cell Signaling Technology, Danvers, MA, USA, #12238) 1:300 for 40 minutes, in the dark at 4 °C. Cells were washed with a FACS buffer (FACS solution supplemented with 4% fetal calf serum) and incubated with anti-rabbit secondary antibody Alexa Fluor 488™ (#4412, Cell Signaling Technology, Danvers, MA, USA)(1:800) for 40 minutes, in the dark at 4 °C. Cells were centrifuged and resuspended in the FACS buffer for acquisition in the flow cytometer. The percentage of Ecto-CRT was counted as Low FSC / CRT⁺ population in the DAPI⁻ cells.

2.10 ERp57 (Ser51) externalization measurement – flow cytometry

Cells were fixed with 0.25% paraformaldehyde in ice-cold PBS for 5 min and incubated with anti-ERp57 (#A484, Rabbit mAb, Cell Signaling Technology, Danvers, MA, USA) 1:100 for 40 minutes, in the dark at 4 °C. Cells were washed with a FACS buffer (FACS solution supplemented with 4% fetal calf serum) and incubated with anti-rabbit secondary antibody conjugated with Alexa Fluor 488™ (1:400) for 40 minutes, in the dark at 4 °C. Cells were centrifuged and resuspended in the FACS buffer for acquisition in the flow cytometer. The mean fluorescence intensity (MFI) related to Ecto-ERp57 was evaluated in the DAPI⁻ population.

201 **2.11 Evaluation of nuclear HMGB1 - flow cytometry**

202 Cell membranes were permeabilized with 0.1% TritonX 100 solution for 5 minutes. Then cells
 203 were washed with PBS and incubated with anti-HMGB1 conjugated with phycoerythrin (PE)
 204 (# 651403, PE anti-HMGB1; Biolegend, San Diego, CA, USA) for 40 min, in the dark at 4 °C.
 205 After incubation, cells were washed, resuspended in the FACS buffer, and acquired in the
 206 flow cytometer. The HMGB1 release was estimated indirectly by the MFI decreasing in cells
 207 exposed to doxorubicin and CA₅₋₈ (GOMEZ-CADENA et al., 2016).

208

209 **2.12 Evaluation of eIF2α and P-eIF2α – flow cytometry**

210 Cell membranes were permeabilized with 0.1% TritonX 100 solution for 5 minutes. Then cells
 211 were washed with PBS and incubated with anti-eIF2α (#9722, Cell Signaling Technology,
 212 Danvers, MA, USA) or anti-P-eIF2α (phospho S51) (#9721, Cell Signaling Technology,
 213 Danvers, MA, USA). Antibodies (1:100) were incubated for 40 min at 4 °C. Subsequently,
 214 these cells were washed and incubated with the secondary antibody conjugated with Alexa
 215 Fluor 488 (Biolegend, San Diego, CA, USA) (1:400) for 40 minutes, in the dark at 4 °C. After
 216 cell wash and resuspension in the FACS buffer, the data were acquired by flow cytometry.
 217 MFI of eIF2α and P-eIF2α was measured in the DAPI⁺ region.

218

219 **2.13 ATP release assay**

220 ATP determination kit (#A22066, ThermoFisher Scientific, Inchinnan, UK) based on luciferin-
 221 luciferase conversion was carried out according to the manufacturer's protocol. Briefly, the
 222 supernatant was centrifuged at 1200 rpm for 5 min and 10 µL of cleared supernatants of each
 223 condition were transferred to a 96-well plate for luminescence. Then, 90 µL of ATP mix
 224 reagent was added to each well. After incubation for 1 min at room temperature, we analyzed

luminescence emission in the multimode microplate reader Cytation 3 (Biotek, Vermont, USA).

227

2.14 Western blot analysis

Total protein extraction was performed using a buffer containing 100 mM Tris (pH 7.6), 1% Triton X-100, 150 mM NaCl, 2 mM PMSF, 10 mM Na₃VO₄, 100 mM NaF, 10 mM Na₄P₂O₇, and 4 mM EDTA. Equal amounts of protein were used from total extracts followed by SDS-PAGE, and Western blot analysis with the antibodies indicated, as previously described (LIPRERI DA SILVA et al., 2021) Antibodies against total and cleaved PARP1 (#9542), LC3BI/II (#2775), and α -tubulin (#2144) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibody against γ -H2AX (p-Histone H2A.X S139; sc-101696) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody binding was revealed using a SuperSignalTM West Dura Extended Duration substrate system (Thermo Fisher Scientific) and a G: BOX Chemi XX6 gel document system (Syngene, Cambridge, UK).

239

2.15 Quantitative RT-PCR (qRT-PCR)

B16-F10 cells were seeded on cell culture dishes (90x15mm) and treated with 0.05% DMSO, chromomycin CA5 (0.1 μ M), or doxorubicin (0.6 μ M) for 24 h. Total RNA was obtained using TRIzol reagent (Thermo Fisher Scientific). cDNA was synthesized from 1 μ g of RNA using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) was performed using a QuantStudio 3 Real-Time PCR System in conjunction with a SybrGreen System (Thermo Fisher Scientific) in conjunction with a SybrGreen System for the expression of *Atf4*, *Atf6*, *Atg5*, *Atg7*, *Bak1*, *Bad*, *Bax*, *Bcl2*, *Becn1*, *Carl*, *Hspa4*, *Hspa5* and *Sqstm1* genes. *Actb* and *Hprt1* were used as reference genes. A negative 'No Template Control' was included for each primer pair. All procedures were performed according to the

250 manufacturer's instructions. Relative quantification values were calculated using the $2^{-\Delta\Delta CT}$
 251 equation (LIVAK; SCHMITTGEN, 2001). The heatmap was constructed using the multiple
 252 experiment viewer (MeV) 4.9.0 software (SAEED et al., 2003). The network analysis was
 253 performed using modulated genes by Dox or CA5 groups using the GeneMANIA tool
 254 (WARDE-FARLEY et al., 2010).

255

256 **2.16 Vaccination assay**

257 The vaccination assay was performed with a syngeneic mouse model as described by
 258 Gomez-Cadena et al., 2016 with modifications. A syngeneic mouse model (e.g., B16-F10 cell
 259 line in C57BL/6 mice), is an appropriate approach to study cancer therapy with a functional
 260 immune system. The vaccination was performed on day -7 when the mice of the 3
 261 experimental groups (N=7 animals/group) received subcutaneously into the right axilla 200
 262 μ L of 0.9% saline solution (Saline), as a negative control, or 200 μ L of dying B16-F10 cells
 263 pre-exposed 24 h to 0.1 μ M CA₅ (CA5) and 0.6 μ M doxorubicin (Dox), as a positive control.
 264 The dying cells were obtained after exposure to cytotoxic agents for 24 h, then harvested,
 265 washed with PBS twice, and resuspended in PBS with 1.8×10^5 cells/200 μ L. No additional
 266 adjuvants were added. Seven days later, on day 0, mice of Saline, CA5, and Dox groups were
 267 challenged with an injection of 1.0×10^5 viable B16-F10 cells in 200 μ L of PBS into the left
 268 armpit subcutaneously. The size of the tumors was measured at days 12, 15, and 17 with
 269 digital calipers. The tumor volume was calculated using the following formula: tumor volume
 270 (in mm^3) = [(width)² × length] / 2.

271

272 **2.17 Statistical analysis**

273 All statistics were performed in GraphPad Prism v6 (GraphPad Software, LLC, San Diego,
 274 CA, USA). Shapiro-Wilk was used to test the normal distribution of results. Data are

expressed as means $\pm$ standard deviation of the mean (SD). Comparisons between C- and treated groups were performed using the One-Way Analysis of Variance (ANOVA) followed by Dunnet's post-test for parametric data and using Kruskal-Wallis followed by Dunn's post-test for nonparametric data. A $p < 0.05$ value was considered significant.

3. Results

3.1 Chromomycins A₅₋₈ are highly cytotoxic at multiple time exposures

Initially, we performed concentration-effect curves with CA₅₋₈ varying time exposure to determine their antiproliferative profile against metastatic melanoma B16-F10 cells (Fig.1). CA₅ and CA₇ were the most potent compounds, depicting low to mid nM cytostatic and cytotoxic effects respectively even at short time exposures (Fig. 1A). In addition, CA₆ also displayed a similar profile at longer exposures. CA₈ induced a potent cytostatic effect, however, it failed to show cytotoxicity at the nM range. Additionally, CA₅₋₈ inhibited colony formation at the nM range of B16-F10 cells incubated for 24 h (Fig. 1B and C).

Figure 1. Antiproliferative profile of chromomycins A₅₋₈ on metastatic melanoma B16-F10 cell line over time. **A**, Graphs showing the antiproliferative activity of CA₅₋₈ after different exposure periods by the SRB assay. Inhibition concentration mean (IC₅₀), total growth inhibition (TGI), and lethal concentration mean (LC₅₀) values were obtained from interpolation of non-linear regression of normalized absorbance of 3 experiments performed in triplicate. **B**, Representative photos of the clonogenic assay, and **C**, Number of colonies represented as the mean ± standard deviation. 0.05% DMSO (C-) and 0.6 μM doxorubicin (Dox) were considered as a negative control and positive control, respectively. Statistical differences of

298 treated groups versus C- are expressed as p values indicated above the columns of the
299 groups.

300

301 3.2 Chromomycins A₅₋₈ induce apoptosis

302 Immunogenic cell death (ICD) determination requires confirmation of early and late apoptotic
303 features (GALLUZZI et al., 2020). B16-F10 cells depicted typical apoptosis features after
304 exposure to CA₅₋₈ such as cell shrinkage (Fig. 2A and Fig. 2B) and PARP1 cleavage (Fig.
305 2D). Notably, CA₅ induced intense PARP1 cleavage compared to the other chromomycins,
306 while the Dox group was similar to C-. All treated groups increased (p<0.0001) the cell death
307 population subset (Fig. 2B and C). Similar to PARP1 cleavage, CA₅₋₈ also induced an
308 increase of γ -H2AX levels, and Dox did not elicit this marker of DNA damage (Fig. 2D).

309

310 **Figure 2. Chromomycins A₅₋₈ induce cellular morphological changes and cell death.** B16-F10
311 melanoma cells were treated with DMSO (C-), as a negative control, doxorubicin (Dox), as a positive
312 control, and CA₅₋₈ (CA5-8) for 24 h. **A**, Phase contrast photomicrographs (200x). **B**, Representative

contour plot graphs of the cell death subpopulation gated in the low forward scatter (FSC) and DAPI+ region by flow cytometry and **C**, the respective graph depicting the percentage of dead cells. Data presented as mean $\pm$ standard deviation of 3 independent experiments performed in triplicate. The *p* values of C- compared to the treated groups are above each treated group. **D**, Expression of cleaved PARP1 and γ H2AX obtained by Western blot. Values associated with test proteins were normalized to standard α -tubulin for the relative expression measure.

3.3 Chromomycins induce autophagy

ICD inducers elicit cell stress associated with cell demise. Autophagy and endoplasmic reticulum (ER) stress are phenotypic changes observed quite often with ICD (GARG; AGOSTINIS, 2014). CA₅₋₈ and Dox significantly increased the granularity of B16-F10 cells (Fig. 3A and B). Additionally, CA₅₋₈ and Dox increased cells with acidic vesicular organelles (AVOs) (Fig. 3C and D), and LC3B I/II levels as well (Fig. 3E). These data confirm the autophagy induction by chromomycins on B16-F10 cells.

Figure 3. Chromomycins A₅₋₈ induce autophagy. B16-F10 melanoma cells were treated with DMSO (C-), as a negative control, doxorubicin (Dox), as a positive control, and CA₅₋₈ (CA5-8) for 24 h. **A**, Representative contour plot graphs of cells with granularity gated on high side scatter (SSC) and average forward scatter (FSC) region by flow cytometry and **B**, the graph depicting the percentage of high granularity cells. **C**, Representative dot plots of acridine orange (AO) staining. Acidic vesicular organelles (AVOs) were gated on the region with increased red fluorescence by flow cytometry and **D**, the graph showing the percentage of AVOs. Data presented in graphs as mean $\pm$ standard deviation of 3 independent experiments performed in triplicate. The *p* values of C- compared to the treated groups are above each treated group. **E**, Expression of LC3B I/II protein with values normalized by standard α -tubulin for the relative expression measure.

3.4 Chromomycins induce the release of ICD related DAMPs

The regulated cell death of B16-F10 exposed to CA₅₋₈ associated with cell stress is a minimal requirement observed in ICD (Fig. 2 and Fig 3). However, the immunogenicity of ICD depends

on the damage-associated molecular patterns (DAMPs) releasing. Several DAMPs related to ICD have been reported so far. Despite this, only a few examples are highly recurrent in ICD, such as secretion of ATP and HMGB1, a nuclear non-histone nuclear factor, and externalization to the plasma membrane of CRT, a luminal chaperone of the ER (KROEMER et al., 2013; RADIOGNA; DICATO; DIEDERICH, 2019; GALLUZZI et al., 2020). We observed nuclear HMGB1 decreasing in B16-F10 cells incubated with CA₅₋₈ and Dox (Fig. 4A and B). ATP levels increased significantly, compared to C-, in supernatants of CA₅ exposed cells, while Dox and CA₆₋₇ did not change the level of this DAMP (Fig. 4C). Additionally, CA₅₋₈ induced CRT externalization in the shrunken cells subpopulation (Fig. 4D, E, and F) and Dox as well. ATP and HMGB1 act as classic DAMPs, with chemoattractant and activation roles on APCs as ligands of purinergic receptors (P2Y₂ and P2X₇) and toll-like receptor 4 respectively. The ecto-CRT is a phagocytic signal recognized by CD91 that promotes antigen presentation of tumor neoantigens in presence of HMGB1 activation (GALLUZZI et al., 2020; GARG et al., 2012).

ICD is a complex phenomenon in which multiple phenotypic changes are required to allow the proper immune system activation. In order to compare the putative ICD potential among compounds used in our pipeline, we scored a total of seven parameters related to cell stress, cell death, and DAMPs from assays performed with CA₅₋₈ and Dox as well (SI.1). The sum of scores for each compound was considered an ICD index, which aided us to understand the overall immunogenic potential profile of compounds tested in this study. CA₅ depicted the highest ICD index followed by CA₆ and CA₇, Dox and CA₈ respectively (Fig. 4G). From this point, we focused on further analyses of the effects of CA₅.

The co-externalization of ERp57 with CRT is the actual “eat me” signal for phagocytosis by the APCs with an activation outcome. The B16-F10 cells exposed to CA₅ and Dox presented ERp57 externalization (Fig. 4H and I). ER stress is an important ICD driver related to

externalization of CRT and ERp57, and could initiate autophagy and apoptosis as well. The eIF2 α is an ER stress protein involved in ICD. Dox-treated cells induced an increase of eIF2 α (Fig. 4J and K), while CA₅ treatment did not change the level of this protein. Nevertheless, the phosphorylation of eIF2 α at Ser51 is the crucial ICD signaling (BEZU et al., 2018; HUMEAU et al., 2020). Cells incubated with CA₅ elicited a significant activation of this protein (Fig. 4L and M). Curiously, Dox did not increase P-eIF2 α levels despite the increase of the overall levels of eIF2 α .

Figure 4. Chromomycins A₅₋₈ induce the release of immunogenic cell death DAMPs. B16-F10 melanoma cells were treated with DMSO (C-), as a negative control, doxorubicin (Dox), as a positive control, and CA₅₋₈ (CA5-8) for 24 h. **A**, Representative histograms of nuclear HMGB1 evaluated by

flow cytometry and **B**, graph depicting normalized median fluorescence intensity (MFI) of nuclear HMGB1. **C**, Normalized extracellular ATP levels measured by luminescence. **D**, Representative contour plot graphs of calreticulin (CRT) vs cell size (forward scatter, FSC) by flow cytometry, **E**, Illustration of the gated region of CRT+ cells with low FSC and **F**, graph depicting the percentage of CRT+ cells. **G**, Radar graph of the index of immunogenic cell death (ICD index). Details of ICD index are described in SI.1. **H**, Representative histograms of ERp57 evaluated by flow cytometry and **I**, graph depicting normalized MFI of ERp57. **J**, Representative histograms of eIF2 α evaluated by flow cytometry and **K**, graph depicting normalized MFI of eIF2 α . **L**, Representative histograms of cells with eIF2 α phosphorylated at serine 51 (P-eIF2 α) evaluated by flow cytometry and **M**, graph depicting normalized MFI of P-eIF2 α . Data presented in graphs as mean $\pm$ standard deviation of 3 independent experiments performed in triplicate. The *p* values of C- compared to the treated groups are above each treated group.

390

391 **3.5 CA₅ impacts gene expression related to autophagy, ER stress, and apoptosis**

392 To obtain new insights into the molecular mechanisms involved in the response of B16-F10
393 cells to CA₅, we investigated the expression of 13 genes related to autophagy, apoptosis, and
394 ER stress by quantitative RT-PCR. A total of 7 of out 13 genes was significantly modulated
395 by CA₅ treatment (6 downregulated [*Atf4*, *Atf6*, *Hspa4*, *Hspa5*, *Atg5*, and *Sqstm1*] and 1
396 upregulated [*Benc1*], all *p*<0.05), while 5 genes were significantly modulated by Dox
397 treatment (4 downregulated [*Atf4*, *Hspa4*, *Hspa5*, and *Atg5*] and 1 upregulated [*Bax*] all
398 *p*<0.05) in B16-F10 cells. Of note, treatment with CA₅, but nor Dox, significantly increased
399 the *Becn1/Bcl2* and *Bad/Bcl2* ratios (Fig. 5A-B). The network analysis indicates that CA₅
400 induces more complex relationships, which effectively interconnects the processes of
401 apoptosis, autophagy, and ER stress (Fig. 5C).

quantitative RT-PCR are illustrated as strikethrough circles, and the interacting genes included by the software modeling are indicated by strikethrough strands. The main interactions between genes are indicated by colored lines and the five main cellular processes are described in the Figure.

3.6 Vaccination of mice with B16-F10 dying cells exposed to CA₅

The vaccination assay using cells dying triggered by a cytotoxic agent is the gold standard technique for ICD confirmation (KEPP et al., 2014). CA₅-exposed cells injected 7 days before the challenge with B16-F10 viable cells developed a significant tumor growth control protection (Fig. 6). This vaccination effect was not observed with mice of the Dox group. It is worth highlighting that the dying cells from CA₅ and Dox groups were washed before injection in a saline solution.

Figure 6. Vaccination with dying B16-F10 cells exposed to chromomycin A₅ confers mice resistance against live B16-F10 cells. At day -7, 1.8×10^5 cells pre-incubated for 24 h with 0.1 μ M CA₅ (CA₅) and 0.6 μ M doxorubicin (Dox) were injected subcutaneously in the right armpit of mice. 7 days after vaccination (day 0) mice were challenged with 1×10^5 live B16-F10 cells in the left armpit. The mice of the negative control group (Saline) were injected with saline solution at -7 day and live B16-F10 cells at day 0. N= 7 mice/group. Tumor growth was monitored until day 17. Differences between groups are expressed as *p* values indicated above the compared groups.

4. Discussion

AMM lacks a therapeutic option to convert immune-cold into immune-hot tumors to improve the clinical response of the patients who do not respond to the current arsenal available including immunotherapy (BONAVENTURA et al., 2019). The identification of ICD inducers

could fill this need by combining two useful effects at once, direct cytotoxicity against tumor cells and release of immunological activating signals. This type of regulated cell death allows the proper activation of the immune system, which in your turn, eliminates tumor cells resistant to chemotherapy. This mechanism is related to more effective and long-lasting responses (ZITVOGEL et al, 2008; ZITVOGEL et al., 2010; VANMEERBEEK et al., 2020). Herein we investigated the ICD induction of four chromomycins obtained from the marine bacterium *Streptomyces* sp. BRA-384 against metastatic melanoma B16-F10 cells.

Initially, the cytostatic and cytotoxic profiles of CA₅₋₈ were investigated with increasing time exposure, and it was observed a time-dependent effect in the nM range. Notably, CA₅ and CA₇ depicted cytotoxicity in low time-exposure of 4 h and 8 h respectively (Fig. 1A). Additionally, CA₅₋₈ completely inhibited colony formation of tumor cells after 24 h incubation (Fig. 1B). These data highlighted a favorable cytotoxic feature of chromomycins as anticancer compounds, which must achieve therapeutic plasma levels in a short time window due to toxicity.

The most reliable approach to the initial identification of ICD still consists in performing multiple phenotypic assays to evaluate autophagy, apoptosis, and releasing of DAMPs on treated cells *in vitro* (GALLUZZI et al, 2020). In general, cells treated with CA₅₋₈ and Dox depicted some ICD features such as apoptosis (Fig. 2), autophagy (Fig. 3) and externalization of CRT, and releasing of HMGB1 (Fig. 4B, and F). Notably, CA₅-treated cells depicted the most consistent ICD profile, filling all phenotypic features investigated so far, followed by CA₆ and CA₇, Dox and CA₈ (Fig. 4G). Dox failed to increase cleaved PARP1 on B16-F10 cells, an apoptosis marker (KAUFMANN et al., 1993; TEWARI et al., 1995) and Dox and CA₆₋₈ all failed to release ATP, an essential DAMP involved in the ICD (KEPP et al., 2014; HUMEAU et al., 2019; VULTAGGIO-POMA; SARTI; VIRGILIO, 2020). CA₅ induced ATP release, ERp57 externalization, and phosphorylation of eIF2 α (Fig. 4C, I and M respectively). Dox increased

461 eIF2 α levels, without significant phosphorylation at serine 51 (Fig. 4K and M). Analyses of
 462 anticancer ICD inducers revealed eIF2 α phosphorylation mediated by eIF2 α kinase-3
 463 (EIF2AK3), but no other signs of ER stress are related to CRT exposure (PANARETAKIS et
 464 al., 2009; BEZU et al., 2018; HUMEAU et al., 2020). Furthermore, machine-learning
 465 approaches revealed eIF2 α phosphorylation as the sole ER stress response relevant to the
 466 algorithm with downstream consequences including CRT exposure, stress granule formation,
 467 and autophagy induction (BEZU et al., 2018; HUMEAU et al., 2020). Although Dox did not
 468 induce a significant increase of phosphorylation of eIF2 α , it induced CRT externalization (Fig.
 469 4F) and increased the high granularity population (Fig. 3A and B) and autophagy (Fig. 3C-E).
 470 This conflicting data could be explained as a masking effect of the increase eIF2 α in Dox-
 471 treated cells (Fig. 4K), which could produce biologically relevant phosphorylation of eIF2 α as
 472 detected by increased ecto-CRT and autophagy.

473 CA₅ and doxorubicin altered expression of transcription of 13 selected genes related to
 474 autophagy, ER stress, and apoptosis. However, CA₅-treated cells changed most of the genes
 475 evaluated and increased the Becl1/Bcl2 and Bad/Bcl2 ratios (Fig. 5A-B) and depicted a wider
 476 interconnected network among apoptosis, autophagy, and ER stress than doxorubicin-treated
 477 cells (Fig. 5C). It is worth highlighting the cellular response to starvation along with ER stress
 478 and apoptosis, as a putative indication of a more intense stress response on CA₅-treated cells
 479 in comparison to Dox. Activating transcription factors *Atf4* and *Atf6* were downregulated
 480 on CA₅ cells (Fig. 5B). Dox treatment also decreased *Atf4*, however did not alter *Atf6*.
 481 ICD inducers, such as anthracyclines, enhance phosphorylation of eIF2 α , but fail to
 482 stimulate other ER stress signs including the transcriptional activation of activating
 483 transcription factor 4 (ATF4) and the proteolytic cleavage of activating transcription factor
 484 6 (ATF6) (BEZU et al., 2018; HUMEAU et al., 2020). The cellular changes induced by
 485 CA₅ are summarized in the Fig. 7 along with the expected effect on dendritic cells.

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

Figure 7. Overview of immunogenic cell death (ICD) induced by chromomycin A₅ (CA₅) in metastatic melanoma. B16-F10 cells treated with CA₅ displayed cell stress and cell death along with release of damage-associated molecular patterns (DAMPs) which are supposed to activate antigen presenting cells (APC) and generating an effective cellular immune response. The phosphorylation of eIF2α due to endoplasmic reticulum (ER) stress drives crucial immunogenic events, as externalization of the “eat me” signals calreticulin (CRT) and ERp57, autophagy and apoptosis. AVOs, acidic vesicular organelles; Casp3, caspase 3; PRRs, pattern recognition receptors; CTLs, cytotoxic T lymphocytes.

The vaccination assay is the gold standard method to confirm ICD, due to its complex spatio-temporal nature. Dying cells undergoing bonafide ICD must effectively recruit and activate both APCs and lymphocytes without any external adjuvants. The vaccination efficacy is evaluated by challenging mice with live cells of the same lineage (KEPP et al., 2014; HUMEAU et al., 2019; VANMEERBEEK et al., 2020). C57BL/6 mice vaccinated with CA₅-

501 treated cells controlled tumor growth efficiently (Fig. 6). At day 17 the mean tumor volume of
502 mice of the CA5 group was significantly lower ($p=0.0001$) than the mean tumor volume of the
503 Saline group. Actually, animals from the CA5 group showed only 20% of the mean saline
504 tumor volume, and one animal did not develop a tumor at all. This result confirms CA₅ as a
505 bonafide ICD inducer. Tumors of the Dox group did not show a significant difference from the
506 negative control ($p = 0.4$). Gomez-Cadena et al. (2016) reported significant tumor control of
507 C57L/6 mice vaccinated with Dox-treated B16-F10 cells. In their study, the cell treatment with
508 doxorubicin was longer (48 h), and caspase 3 activation confirmed apoptosis induction.
509 However, the ATP levels in supernatants of Dox-treated cells did not increase either, similar
510 to our results as we found in the present study.

511 Fine-tuning *in vitro* conditions to confirm the induction of ICD is challenging and some studies
512 could fail to demonstrate it depending on the histological origin of cells and time and
513 concentrations of exposure used as well (SUKKURWALA et al., 2014). Most ICD inducers,
514 such as doxorubicin, oxaliplatin, bortezomib and vinca alkaloids, were identified using tumor
515 cell lines from different tumor origins of clinical practice (MENGER et al., 2012;
516 SUKKURWALA et al., 2014). Although this approach generated robust knowledge about ICD
517 inducers initially, it led to delayed identification of some important ICD inducer anticancer
518 agents, including paclitaxel and cisplatin (LAU et al., 2020; SOLARI et al., 2020). Similarly,
519 other chromomycins, including CA₇₋₈ studied here, also induce ICD depending on
520 experimental design; however further studies are needed to fully characterize ICD triggered
521 by chromomycins. Additionally, the suboptimal results we obtained with melanoma cells
522 exposed to doxorubicin, an important ICD inducer used in the treatment of several solid and
523 hematological cancers (e.g. breast, ovary, prostate and multiple myeloma), also illustrates
524 the challenge of identifying experimental conditions that trigger ICD.

A few chemotherapeutic agents are known to induce ICD, and they demonstrate remarkable clinical performance (KEPP; SENOVILLA; KROEMER, 2014), CA₅ shows evidence of ICD and thus is a highly promising candidate for AMM and deserves further preclinical studies. It is also worth highlighting the supply as one important bottleneck to the preclinical and clinical development of pharmaceuticals (JIMENEZ et al., 2020). We obtained CA₅ for this study using a sustainable and easily scalable technique (PINTO et al., 2019), and its supply for studies *in vivo* is quite feasible. In summary, we identified CA₅ as a bonafide inducer of ICD in metastatic melanoma cells. Further *in vivo* studies with CA₅ are necessary to evaluate antitumor activity, toxicity, and survival, as well as the effect on CA₅ associated with immunotherapy.

Acknowledgements

We thank to Dr. Margo Haygood for reviewing the manuscript. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001, Instituto Nacional de Ciência e Tecnologia (INCT BioNat-CNPq/FAPESP, No. 465637/2014-0) and Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/23864-7). The authors also thank the Multi-User Facility of Drug Research and Development Center of Federal University of Ceará for technical support.

Conflict of Interest

None.

Author Contributions

Katharine Gurgel Dias Florêncio: Methodology, Validation, Writing - Original Draft, Formal analysis, Investigation, Visualization **Eveline Araújo Edson:** Methodology, Validation, Investigation, Formal analysis **Francisco das Chagas Lima Pinto:** Methodology, Validation,

Investigation **Otília Deusdênia Loiola Pessoa**: Validation, review the manuscript **João Agostinho Machado Neto**: Methodology, Validation, Formal analysis, Investigation **Diego Veras Wilke**: Conceptualization, Funding acquisition, Supervision, Validation, Writing - Review & Editing.

554

555 **References**

556 ATKINS, B. M. B. et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With
557 Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. 2016.

558 BEZU, L. et al. eIF2 α phosphorylation is pathognomonic for immunogenic cell death. **Cell**
559 **Death & Differentiation**, v. 25, p. 1375 – 1393, 2018.

560 BONAVENTURA, P. et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy.
561 **Frontiers in Immunology**, v. 10, p. 168, 2019.

562 BROWN AND TORKELOSON. Long-term follow-up stage III testicular carcinoma treated with
563 mithramycin (plicamycin). **Med Pediatr Oncol**, v. 24, p. 327–328, 1995.

564 CHAKRABORTY, H. et al. **New Functions of Old Drugs: Aureolic Acid Group of Anti-**
565 **Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs**. [s.l.] Elsevier, 2014. v. 1

566 DUTCHER, J. P. et al. A pilot study of alpha-interferon and plicamycin for accelerated phase
567 of chronic myeloid leukemia. **Leukemia Research**, v. 21, n. 5, p. 375–380, 1997.

568 FRANKEN, N. A. P. et al. Clonogenic assay of cells in vitro. **Nature Protocols**, v. 1, n. 5, p.
569 2315–2319, 2006.

570 GALLUZZI, L. et al. Immunogenic cell death in cancer and infectious disease. **Nature**
571 **Reviews Immunology**, v. 17, n. 2, p. 97–111, 2017.

572 GALLUZZI, L. et al. Consensus guidelines for the definition, detection and interpretation of
573 immunogenic cell death. **Journal for ImmunoTherapy of Cancer**, v. 8, n. 1, p. 1–22, 2020.

574 GARG, A. D. et al. A novel pathway combining calreticulin exposure and ATP secretion in

immunogenic cancer cell death. **The EMBO Journal**, v. 31, n. 5, p. 1062–1079, 2012.

GARG, A. D. et al. Danger signalling during cancer cell death: Origins, plasticity and regulation. **Cell Death and Differentiation**, v. 21, n. 1, p. 26–38, 2014.

GARG, A. D.; AGOSTINIS, P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. **Photochemical and Photobiological Sciences**, v. 13, n. 3, p. 474–487, 2014.

GOMEZ-CADENA, A. et al. Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. **Cell Death and Disease**, v. 7, n. 6, p. 1–12, 2016.

GUIMARÃES, L. A. et al. Chromomycin A2 induces autophagy in melanoma cells. **Marine Drugs**, v. 12, n. 12, p. 5839–5855, 2014.

HUMEAU, J. et al. Gold standard assessment of immunogenic cell death in oncological mouse models. **Methods in Molecular Biology**, v. 1884, p. 297–315, 2019.

HUMEAU, J. et al. EIF2 α phosphorylation: a hallmark of both autophagy and immunogenic cell death. **Molecular and Cellular Oncology**, v. 7, n. 5, 2020.

JIMENEZ, P. C. et al. Enriching cancer pharmacology with drugs of marine origin. n. February 2019, p. 3–27, 2020.

KAKADIA, S. et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. **OncoTargets and Therapy**, p. 7095–7107, 2018.

KAUFMANN, S. H. et al. Specific Proteolytic Cleavage of Poly (ADP-ribose) Polymerase : An Early Marker of. **Cancer Research**, v. 53, p. 3976–3985, 1993.

KEPP, O. et al. Consensus guidelines for the detection of immunogenic cell death. **OncolImmunology**, v. 3, n. 9, p. 37–41, 2014.

KEPP, O. et al. Clinical evidence that immunogenic cell death sensitizes to PD-1 / PD-L1

blockade Clinical evidence that immunogenic cell death sensitizes to PD-1 / PD-L1 blockade.
OncImmunology, v. 8:10, p. 1–4, 2019.

KEPP, O.; SENOVILLA, L.; KROEMER, G. Immunogenic cell death inducers as anticancer
agents. **Oncotarget**, v. 5 (14), p. 5190–5191, 2014.

KORMANEC, J. et al. The antitumor antibiotic mithramycin: new advanced approaches in
modification and production. **Applied Microbiology and Biotechnology**, v. 104, n. 18, p.
7701–7721, 2020.

KROEMER, G. et al. Immunogenic cell death in cancer therapy. **Annual Review of
Immunology**, v. 31, p. 51–72, 2013.

LARKIN, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated
Melanoma. **New England Journal of Medicine**, v. 373, n. 13, p. 1270–1271, 2015.

LAU, T. S. et al. Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4 /
IKK2 / SNARE-Dependent Exocytosis. **Cancer Immunology Research**, p. 1099–1112,
2020.

LAURENCE, Z.; KROEMER, L. A. F. G. AND G. Immunological aspects of cancer
chemotherapy. v. 8, n. january, p. 59–73, 2008.

LIPRERI DA SILVA, J. C. et al. Comprehensive analysis of cytoskeleton regulatory genes
identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.
Cellular Oncology, 2021.

LIVAK, K. J.; SCHMITTGEN, T. D. Analysis of relative gene expression data using real-time
quantitative PCR and the 2- $\Delta\Delta$ CT method. **Methods**, v. 25, n. 4, p. 402–408, 2001.

MARTINS, I. et al. Premortem autophagy determines the immunogenicity of chemotherapy-
induced cancer cell death. **Autophagy**, v. 8:3, p. 413–415, 2012.

MENGER, L. et al. Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic
Cell Death. **Sci Transl Med**, v. 4(143), 2012.

625 PANARETAKIS, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic
626 cell death. **EMBO Journal**, v. 28, n. 5, p. 578–590, 2009.

627 PINTO, F. C. et al. Dextrorotatory Chromomycins from the Marine. v. 31, n. 0, p. 1–10, 2019.

628 QUEIROLO, P. et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma:
629 a model of cancer immunotherapy. **Seminars in Cancer Biology**, n. June, p. 0–1, 2019.

630 RADOGNA, F.; DICATO, M.; DIEDERICH, M. Natural modulators of the hallmarks of
631 immunogenic cell death. **Biochemical Pharmacology**, v. 162, n. January, p. 55–70, 2019.

632 SAEED, A. I. et al. TM4: A free, open-source system for microarray data management and
633 analysis. **BioTechniques**, v. 34, n. 2, p. 374–378, 2003.

634 SAHM, B. D. B. et al. Targeting the Oncogenic TBX2 Transcription Factor With
635 Chromomycins. **Frontiers in Chemistry**, v. 8, n. March, p. 1–9, 2020.

636 SKEHAN, P. et al. New Colorimetric Cytotoxicity Assay for. **Journal of the National Cancer**
637 **Institute**, v. 82, n. 13, p. 1107–1112, 1990.

638 SNYDER, R. C. et al. Mithramycin Blocks Transcriptional Initiation of the c-myc P1 and P2
639 Promoters. **Biochemistry**, v. 30, n. 17, p. 4290–4297, 1991.

640 SOLARI, J. I. G. et al. Damage-associated molecular patterns (DAMPs) related to
641 immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in
642 lung adenocarcinoma cells. **BMC Cancer**, v. 20, n. 1, p. 1–14, 2020.

643 SUKANYA CHAKRABARTI¹, D. D. AND; BHATTACHARYYA, D. Role of Mg²⁺ in
644 Chromomycin A3 –DNA Interaction: A Molecular Modeling Study. **Journal of Biological**
645 **Physics**, v. 26, n. 1–4, p. 203–214, 2000.

646 SUKKURWALA, A. Q. et al. Screening of novel immunogenic cell death inducers within the
647 NCI mechanistic diversity set. **OncolImmunology**, v. 3, n. 4, 2014.

648 TAGASHIRA, M; KITAGAWA, T; ISONISHI, S; OKAMOTO, A; OCHIAI, K. AND O. Y.
649 Mithramycin Represses MDR1 Gene Expression in Vivo, Modulating Multidrug Resistance.

650 **Biol Pharm Bull**, v. 23, n. 8, p. 926–929, 2000.

651 TEWARI, M. et al. Yama / CPP3213 , a Mammalian Homolog of CED-3 , Is a CrmA-Inhibitable
652 Protease That Cleaves the Death Substrate Poly (ADP-Ribose) Polymerase. v. 81, p. 801–
653 809, 1995.

654 THOMÉ, M. P. et al. Ratiometric analysis of Acridine Orange staining in the study of acidic
655 organelles and autophagy. **Journal of Cell Science**, v. 129, n. 24, p. 4622–4632, 2016.

656 VANMEERBEEK, I. et al. Trial watch: chemotherapy-induced immunogenic cell death in
657 immuno-oncology. **OncolImmunology**, v. 9, n. 1, 2020.

658 VULTAGGIO-POMA, V.; SARTI, A. C.; VIRGILIO, F. DI. Extracellular ATP : A Feasible Target
659 for Cancer Therapy. 2020.

660 WARDE-FARLEY, D. et al. The GeneMANIA prediction server: Biological network integration
661 for gene prioritization and predicting gene function. **Nucleic Acids Research**, v. 38, n.
662 SUPPL. 2, p. 214–220, 2010.

663 ZITVOGEL, L. et al. Immunogenic Tumor Cell Death for Optimal Anticancer Therapy : The
664 Calreticulin Exposure Pathway. 2010.

665

666

667

668

669

670

671

672

673

674

Supplementary information

Chromomycin A₅ induces bonafide immunogenic cell death in metastatic melanoma

Katharine G. D. Florêncio¹, Evelline A. Edson¹, João Agostinho Machado-Neto², Francisco C. L. Pinto³, Otília D. L. Pessoa³ and Diego V. Wilke^{1,*}

SI.1. Immunogenic cell death (ICD) index. Seven parameters related to cell stress, cell death, and release of DAMPs from assays performed with CA₅₋₈ and Dox were scored, based on statistical significance compared to negative control (C-) as 0 when $p > 0.05$; 1 for cytotoxicity and autophagy parameters with $p < 0.05$; and 2 for DAMPs releasing* with $p < 0.05$. The sum of scores for each compound was considered the ICD index.

Cellular phenotype		C-	Dox	CA5	CA6	CA7	CA8
Citotoxicity	Membrane disruption	0	1	1	1	1	1
	Cleaved PARP1	0	0	1	1	1	1
Autophagy	AVOs	0	1	1	1	1	1
	LC3B I/II	0	1	1	1	1	1
DAMP releasing	HMGB1	0	2	2	2	2	2
	ATP	0	0	2	0	0	0
	CRT	0	2	2	2	2	0
ICD index (sum)		0	7	10	8	8	6

*The higher value of score for DAMPs releasing was arbitrarily chosen as an attempt to represent their critical importance on ICD induction.